# Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

> **NCT06852768** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regenerative Ocular Immunobiologics LLC** · enrollment: 1 (estimated)

## Conditions studied

- oGHVD

## Interventions

- **BIOLOGICAL:** d-MAPPS
- **BIOLOGICAL:** Placebo
- **OTHER:** PI and Patient Masked

## Key facts

- **NCT ID:** NCT06852768
- **Lead sponsor:** Regenerative Ocular Immunobiologics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06852768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06852768, "Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06852768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*